Maria L. Ascierto, Ph.D. Saint John's Cancer Institute

Saint John's Cancer Institute's Director of Translational Immunology, Maria L. Ascierto, Ph.D. Contact Dr. Ascierto via email or phone number.

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021 in: Journal of the National Comprehensive Cancer Network Volume 19 Issue 4 (2021)

Melanoma and Cutaneous Oncology - Saint John's Cancer Institute

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

Maria Libera Ascierto on LinkedIn: #aacr19

Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity

Pioneers in Immunotherapy - Saint John's Health Center Foundation

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial - Journal of Thoracic Oncology

Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

Resolving Cancer Heterogeneity: - PDF Free Download

Antoni Ribas – UCLA Graduate Programs in Bioscience (GPB)

Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation - Yu - 2022 - Advanced Science - Wiley Online Library

Paolo ASCIERTO, Director, Director, Istituto Nazionale Tumori Fondazione Pascale, Naples, IRCCS, S.C. Oncologia Medica Melanoma, Immunoterapia Oncologica e Terapie Innovative

Santa Monica Melanoma Symposium - A CME Event - April 30th, 2022 - Saint John's Cancer Institute

Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools

(PDF) Immune evasion in cancer: Mechanistic basis and therapeutic strategies